Emcure Pharmaceuticals Past Earnings Performance
Past criteria checks 2/6
Emcure Pharmaceuticals has been growing earnings at an average annual rate of 24.3%, while the Pharmaceuticals industry saw earnings growing at 15.5% annually. Revenues have been growing at an average rate of 6.4% per year. Emcure Pharmaceuticals's return on equity is 16.9%, and it has net margins of 7.4%.
Key information
24.3%
Earnings growth rate
24.3%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 6.4% |
| Return on equity | 16.9% |
| Net Margin | 7.4% |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Emcure Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 67,152 | 4,982 | 12,921 | 0 |
| 31 Mar 23 | 60,317 | 5,320 | 11,173 | 0 |
| 31 Mar 21 | 60,564 | 3,921 | 12,263 | 0 |
| 31 Mar 20 | 50,486 | 836 | 12,995 | 0 |
| 31 Mar 19 | 47,172 | 1,893 | 12,092 | 0 |
Quality Earnings: EMCURE has high quality earnings.
Growing Profit Margin: EMCURE's current net profit margins (7.4%) are lower than last year (8.8%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: EMCURE's earnings have grown significantly by 24.3% per year over the past 5 years.
Accelerating Growth: EMCURE's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: EMCURE had negative earnings growth (-6.4%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (17%).
Return on Equity
High ROE: EMCURE's Return on Equity (16.9%) is considered low.